Brief: Reviva Announces Enrollment Completion For Pivotal Phase 3 Recover Study For Brilaroxazine In Schizophrenia

Reviva Pharmaceuticals Holdings

17/08/2023 11:01

Reviva Pharmaceuticals Holdings, Inc.  RVPH.O :
    * REVIVA ANNOUNCES ENROLLMENT COMPLETION FOR PIVOTAL PHASE 3
RECOVER STUDY FOR BRILAROXAZINE IN SCHIZOPHRENIA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - TOPLINE DATA FOR
PHASE 3
RECOVER STUDY EXPECTED IN OCTOBER 2023
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - COMPLETION OF
1-YEAR
OPEN-LABEL EXTENSION CLINICAL STUDY EXPECTED IN Q3 2024
    * REVIVA PHARMACEUTICALS HOLDINGS, INC.: TOPLINE DATA FOR
PHASE 3
RECOVER STUDY EXPECTED IN OCTOBER 2023

Source text for Eikon:  ID:nGNX6gFbx7 
Further company coverage:  RVPH.O